NAMS Menopause Certification Exam
2026/2027 | Newly Released| Latest Update
100 Questions with Verified Answers & Rationales
Graded A+| 100% Correct | Guaranteed Pass
Q1: According to the STRAW+10 staging system, what is the defining characteristic of the Early
Menopausal Transition (Stage -2)?
A. Amenorrhea of 60 days or longer
B. Persistent elevation of FSH > 25 IU/L
C. Variable cycle length of 7 days or more difference in consecutive cycles
D. 12 months of amenorrhea
Correct Answer: C
Rationale: Correct because the STRAW+10 criteria define the Early Menopausal Transition
(Stage -2) primarily by a persistent increase in the variability of menstrual cycle length,
specifically a difference of 7 days or more between consecutive cycles. Stages -1 and +1 are
defined by amenorrhea intervals of 60+ days and 12 months, respectively.
Q2: A 58-year-old woman with a uterus asks about the risks of breast cancer associated with
hormone therapy. Based on current evidence, which statement is accurate regarding estrogen-
progestogen therapy (EPT) compared to estrogen-only therapy (ET)?
A. EPT decreases the risk of breast cancer compared to ET.
B. EPT increases the risk of breast cancer more than ET.
C. ET and EPT carry the same risk of breast cancer.
D. Neither ET nor EPT affects breast cancer risk.
Correct Answer: B
Rationale: Correct because data from the Women’s Health Initiative (WHI) and meta-analyses
indicate that combined estrogen-progestogen therapy increases the risk of breast cancer more
than estrogen-only therapy, particularly after 3 to 5 years of use. Estrogen-alone therapy in
women with a prior hysterectomy may show a slight decrease or no increase in breast cancer
risk in some studies.
,Q3: [Case Study] A 48-year-old woman presents reporting that her menstrual cycles, previously
regular every 28 days, have now varied from 21 to 35 days over the last 6 months. She
experiences occasional hot flashes. She is sexually active and does not desire pregnancy. Which
laboratory test is most useful to confirm her menopausal transition status?
A. Serum Follicle Stimulating Hormone (FSH)
B. Serum Anti-Müllerian Hormone (AMH)
C. Serum Estradiol
D. Thyroid Stimulating Hormone (TSH)
Correct Answer: B
Rationale: Correct while FSH and estradiol fluctuate significantly during the menopausal
transition and are less reliable for staging, AMH is a robust biomarker of ovarian reserve that
declines steadily and becomes undetectable earlier in the transition. NAMS guidelines
acknowledge that AMH provides the earliest indication of diminished ovarian reserve, though
clinical assessment often relies on menstrual history.
Q4: A 55-year-old woman with a body mass index (BMI) of 32 kg/m² asks about her hormone
levels. How does obesity typically impact estradiol levels in postmenopausal women?
A. Obesity leads to significantly lower estradiol levels due to increased clearance.
B. Obesity has no impact on estradiol levels after menopause.
C. Obesity is associated with higher circulating estradiol levels due to peripheral
aromatization of androgens in adipose tissue.
D. Obesity increases FSH levels which suppresses estradiol.
Correct Answer: C
Rationale: Correct because adipose tissue contains the enzyme aromatase, which converts
androgens (specifically androstenedione) into estrone and estradiol, leading to higher
circulating estrogen levels in obese postmenopausal women. This mechanism contributes to the
increased risk of endometrial cancer and potentially reduces the severity of vasomotor
symptoms in this population.
,Q5: A patient with a history of deep vein thrombosis (DVT) 3 years ago associated with
pregnancy suffers from severe dyspareunia due to vaginal atrophy. What is the most appropriate
initial treatment for her Genitourinary Syndrome of Menopause (GSM)?
A. Oral conjugated equine estrogens
B. Transdermal estradiol patch
C. Vaginal estradiol tablet or ring
D. Systemic estrogen-progestogen therapy
Correct Answer: C
Rationale: Correct because vaginal estrogen therapy results in very low systemic absorption,
generally keeping serum estradiol levels within the postmenopausal range and posing a minimal
risk of thromboembolism. NAMS position statements support the use of low-dose vaginal
estrogen for GSM symptoms in women with a history of VTE, acknowledging that the risk-
benefit ratio favors treatment over the risks associated with systemic therapy.
Q6: Which non-hormonal medication has the strongest evidence base for the treatment of
moderate-to-severe vasomotor symptoms?
A. Gabapentin
B. Paroxetine 7.5 mg
C. Clonidine
D. Vitamin E
Correct Answer: B
Rationale: Correct because paroxetine 7.5 mg (a low-dose selective serotonin reuptake
inhibitor) is FDA-approved specifically for the treatment of moderate-to-severe vasomotor
symptoms associated with menopause. While gabapentin and clonidine are also used off-label,
paroxetine 7.5 mg has the most robust clinical trial data supporting its efficacy for this
indication.
Q7: A 52-year-old woman presents with hot flashes occurring 6 to 8 times per day and night
sweats disrupting her sleep. She has a history of stage 1 endometrial cancer treated with
, hysterectomy and bilateral salpingo-oophorectomy 2 years ago. She has no contraindications to
estrogen therapy. What is the most appropriate treatment for her vasomotor symptoms (VMS)?
A. Combined conjugated equine estrogens (CEE) and medroxyprogesterone acetate (MPA)
B. Oral estrogen-only therapy
C. Venlafaxine
D. Black cohosh
Correct Answer: B
Rationale: Correct because estrogen-only therapy is the most effective treatment for vasomotor
symptoms and is safe for this patient since she no longer has a uterus, eliminating the risk of
endometrial hyperplasia associated with unopposed estrogen. According to NAMS guidelines,
women without a uterus do not require progestogen for endometrial protection.
Q8: A 62-year-old woman presents with a T-score of -2.8 at the femoral neck and a history of a
fragility fracture. She has no history of breast cancer or thromboembolism. Which
pharmacologic agent is the most appropriate first-line treatment for her osteoporosis?
A. Raloxifene
B. Alendronate
C. Estrogen therapy
D. Calcitonin
Correct Answer: B
Rationale: Correct because bisphosphonates, such as alendronate, are recommended as first-
line pharmacologic therapy for postmenopausal osteoporosis due to their proven ability to
reduce fracture risk at both vertebral and non-vertebral sites. While estrogen is approved for
osteoporosis prevention, bisphosphonates are generally preferred for treatment in older women
with established osteoporosis.
Q9: A 51-year-old woman with an intact uterus is starting systemic hormone therapy. She is
concerned about the side effects of progestogens. Which progestogen is associated with the most
favorable lipid profile and potentially less adverse effect on cardiovascular risk markers?
A. Medroxyprogesterone acetate (MPA)
B. Norethindrone acetate (NETA)
C. Micronized progesterone
D. Levonorgestrel
Correct Answer: C
2026/2027 | Newly Released| Latest Update
100 Questions with Verified Answers & Rationales
Graded A+| 100% Correct | Guaranteed Pass
Q1: According to the STRAW+10 staging system, what is the defining characteristic of the Early
Menopausal Transition (Stage -2)?
A. Amenorrhea of 60 days or longer
B. Persistent elevation of FSH > 25 IU/L
C. Variable cycle length of 7 days or more difference in consecutive cycles
D. 12 months of amenorrhea
Correct Answer: C
Rationale: Correct because the STRAW+10 criteria define the Early Menopausal Transition
(Stage -2) primarily by a persistent increase in the variability of menstrual cycle length,
specifically a difference of 7 days or more between consecutive cycles. Stages -1 and +1 are
defined by amenorrhea intervals of 60+ days and 12 months, respectively.
Q2: A 58-year-old woman with a uterus asks about the risks of breast cancer associated with
hormone therapy. Based on current evidence, which statement is accurate regarding estrogen-
progestogen therapy (EPT) compared to estrogen-only therapy (ET)?
A. EPT decreases the risk of breast cancer compared to ET.
B. EPT increases the risk of breast cancer more than ET.
C. ET and EPT carry the same risk of breast cancer.
D. Neither ET nor EPT affects breast cancer risk.
Correct Answer: B
Rationale: Correct because data from the Women’s Health Initiative (WHI) and meta-analyses
indicate that combined estrogen-progestogen therapy increases the risk of breast cancer more
than estrogen-only therapy, particularly after 3 to 5 years of use. Estrogen-alone therapy in
women with a prior hysterectomy may show a slight decrease or no increase in breast cancer
risk in some studies.
,Q3: [Case Study] A 48-year-old woman presents reporting that her menstrual cycles, previously
regular every 28 days, have now varied from 21 to 35 days over the last 6 months. She
experiences occasional hot flashes. She is sexually active and does not desire pregnancy. Which
laboratory test is most useful to confirm her menopausal transition status?
A. Serum Follicle Stimulating Hormone (FSH)
B. Serum Anti-Müllerian Hormone (AMH)
C. Serum Estradiol
D. Thyroid Stimulating Hormone (TSH)
Correct Answer: B
Rationale: Correct while FSH and estradiol fluctuate significantly during the menopausal
transition and are less reliable for staging, AMH is a robust biomarker of ovarian reserve that
declines steadily and becomes undetectable earlier in the transition. NAMS guidelines
acknowledge that AMH provides the earliest indication of diminished ovarian reserve, though
clinical assessment often relies on menstrual history.
Q4: A 55-year-old woman with a body mass index (BMI) of 32 kg/m² asks about her hormone
levels. How does obesity typically impact estradiol levels in postmenopausal women?
A. Obesity leads to significantly lower estradiol levels due to increased clearance.
B. Obesity has no impact on estradiol levels after menopause.
C. Obesity is associated with higher circulating estradiol levels due to peripheral
aromatization of androgens in adipose tissue.
D. Obesity increases FSH levels which suppresses estradiol.
Correct Answer: C
Rationale: Correct because adipose tissue contains the enzyme aromatase, which converts
androgens (specifically androstenedione) into estrone and estradiol, leading to higher
circulating estrogen levels in obese postmenopausal women. This mechanism contributes to the
increased risk of endometrial cancer and potentially reduces the severity of vasomotor
symptoms in this population.
,Q5: A patient with a history of deep vein thrombosis (DVT) 3 years ago associated with
pregnancy suffers from severe dyspareunia due to vaginal atrophy. What is the most appropriate
initial treatment for her Genitourinary Syndrome of Menopause (GSM)?
A. Oral conjugated equine estrogens
B. Transdermal estradiol patch
C. Vaginal estradiol tablet or ring
D. Systemic estrogen-progestogen therapy
Correct Answer: C
Rationale: Correct because vaginal estrogen therapy results in very low systemic absorption,
generally keeping serum estradiol levels within the postmenopausal range and posing a minimal
risk of thromboembolism. NAMS position statements support the use of low-dose vaginal
estrogen for GSM symptoms in women with a history of VTE, acknowledging that the risk-
benefit ratio favors treatment over the risks associated with systemic therapy.
Q6: Which non-hormonal medication has the strongest evidence base for the treatment of
moderate-to-severe vasomotor symptoms?
A. Gabapentin
B. Paroxetine 7.5 mg
C. Clonidine
D. Vitamin E
Correct Answer: B
Rationale: Correct because paroxetine 7.5 mg (a low-dose selective serotonin reuptake
inhibitor) is FDA-approved specifically for the treatment of moderate-to-severe vasomotor
symptoms associated with menopause. While gabapentin and clonidine are also used off-label,
paroxetine 7.5 mg has the most robust clinical trial data supporting its efficacy for this
indication.
Q7: A 52-year-old woman presents with hot flashes occurring 6 to 8 times per day and night
sweats disrupting her sleep. She has a history of stage 1 endometrial cancer treated with
, hysterectomy and bilateral salpingo-oophorectomy 2 years ago. She has no contraindications to
estrogen therapy. What is the most appropriate treatment for her vasomotor symptoms (VMS)?
A. Combined conjugated equine estrogens (CEE) and medroxyprogesterone acetate (MPA)
B. Oral estrogen-only therapy
C. Venlafaxine
D. Black cohosh
Correct Answer: B
Rationale: Correct because estrogen-only therapy is the most effective treatment for vasomotor
symptoms and is safe for this patient since she no longer has a uterus, eliminating the risk of
endometrial hyperplasia associated with unopposed estrogen. According to NAMS guidelines,
women without a uterus do not require progestogen for endometrial protection.
Q8: A 62-year-old woman presents with a T-score of -2.8 at the femoral neck and a history of a
fragility fracture. She has no history of breast cancer or thromboembolism. Which
pharmacologic agent is the most appropriate first-line treatment for her osteoporosis?
A. Raloxifene
B. Alendronate
C. Estrogen therapy
D. Calcitonin
Correct Answer: B
Rationale: Correct because bisphosphonates, such as alendronate, are recommended as first-
line pharmacologic therapy for postmenopausal osteoporosis due to their proven ability to
reduce fracture risk at both vertebral and non-vertebral sites. While estrogen is approved for
osteoporosis prevention, bisphosphonates are generally preferred for treatment in older women
with established osteoporosis.
Q9: A 51-year-old woman with an intact uterus is starting systemic hormone therapy. She is
concerned about the side effects of progestogens. Which progestogen is associated with the most
favorable lipid profile and potentially less adverse effect on cardiovascular risk markers?
A. Medroxyprogesterone acetate (MPA)
B. Norethindrone acetate (NETA)
C. Micronized progesterone
D. Levonorgestrel
Correct Answer: C
